HEC-68498 is under clinical development by HEC Pharma and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HEC-68498’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HEC-68498 overview

HEC-68498 is under development for the treatment of idiopathic pulmonary fibrosis and solid tumors including colorectal cancer, breast cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), triple negative breast cancer and neuroendocrine cancers. The drug candidate is administered through oral route. It acts by targeting phosphatidylinositol 3 Kinase (PI3K) and mechanistic target of rapamycin (mTOR).

HEC Pharma overview

HEC Pharma is a private company, The Company mainly develops, produces, and distributes active pharmaceutical ingredients, insulins, and more. It is headquartered in Dongguan, Guangdong, China.

For a complete picture of HEC-68498’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.